EFFECT OF PROPOFOL IN CARDIOPLEGIA SOLUTION ON BIOMARKERS OF MYOCARDIAL INJURY IN CORONARY ARTERY BYPASS GRAFTING SURGERY: A RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL

Received 2020-02-03; Accepted 2020-09-14; Published 2021-02-18

Authors

  • Reza Jouybar Anesthesiology and Critical Care Research Center, Shiraz University of Medical Science, Shiraz, Iran.
  • GholamAli Heidari Anesthesiology and Critical Care Research Center, Shiraz University of Medical Science, Shiraz, Iran.
  • Reza Khajeh Anesthesiology and Critical Care Research Center, Shiraz University of Medical Science, Shiraz, Iran.
  • Hojatollah Najafi Health Human Resources Research Center, Department of Health in Disasters and Emergencies, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Elham Asadpour Anesthesiology and Critical Care Research Center, Shiraz University of Medical Science, Shiraz, Iran.
  • Zahra Esmaeilinezhad Anesthesiology and Critical Care Research Center, Shiraz University of Medical Science, Shiraz, Iran.

DOI:

https://doi.org/10.22452/jummec.vol24no1.5

Keywords:

Coronary Artery Bypass Graft surgery, Cardioplegic Solution, Cardiac Protection, Propofol

Abstract

Introduction: Coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB) triggers an inflammatory reaction, leading to the development of myocardial damage and dysfunction. It is assumed that propofol, a general anesthetic agent, has a protective role against oxidative stress. The aim of this study was to evaluate the effect of propofol on myocardial protection when added to cardioplegic solution in patients undergoing CABG.

Methods: In this prospective and double-blind RCT study, 120 patients undergoing CABG surgery were randomly assigned into two equal groups. In one group, we added 1200 µg/min (ultimate dose 4 µg/ml) propofol to cardioplegic solution and in the control group, an equal volume of normal saline was added to cardioplegic solution. Serum levels of CPK-MB and Troponin I were checked at four time points, including: just after induction (T1) as baseline, after chest closure (T2), 6 hours after arrival to ICU (T3) and 24 hours after ICU admission (T4).

Results: Cardiac enzyme levels had significant increase over time in both groups (p-value <0.05). It was observed that the enzyme levels in the propofol group increased less compared with the control group; however, this difference was not significant. Both groups were also similar in incidence of post-operative arrhythmia and need for use of IABP.

Conclusion: Adding a dose of 1200 µg/min (ultimate dose 4 µg/mL) propofol to cardioplegia solution does not have an effect on CPK-MB & troponin I level.

Downloads

Download data is not yet available.

Downloads

Published

2021-02-18

Issue

Vol. 24 No. 1 (2021)

Section

Research article

License

All authors agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0 to allow others to freely access, copy and use research provided the author is correctly attributed, unless otherwise stated. All articles are available online without charge or other barriers to access. However, anyone wishing to reproduce large quantities of an article (250+) should inform the publisher. Any opinion expressed in the articles are those of the authors and do not reflect that of the University of Malaya, 50603 Kuala Lumpur, Malaysia.